Alemtuzumab has historically been used in the treatment of chronic lymphocytic leukaemia and is now used in multiple sclerosis, because of its ability to deplete CD52+ lymphocytes.25 The gene discussed is CD52; the disease is B-cell chronic lymphocytic leukemia.